$599

Vertex New Trial for T1DM Cell Therapy; Novo New Oral Anti-Inflammatory Study; Novo Leadership Transition; Pfizer Amylin Market-Shaping Campaign

A series of cardiometabolic-related news items has been observed from Vertex, Novo Nordisk, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here